Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.

[1]  P. Rojnuckarin,et al.  Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience , 2018, Hematology.

[2]  F. Cavalli,et al.  Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. , 2017, The Lancet. Haematology.

[3]  K. Ohtomo,et al.  Combined intravitreal methotrexate and immunochemotherapy followed by reduced‐dose whole‐brain radiotherapy for newly diagnosed B‐cell primary intraocular lymphoma , 2017, British journal of haematology.

[4]  O. Visser,et al.  Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015 , 2017, Leukemia.

[5]  R. Fimmers,et al.  Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial , 2017, Journal of Cancer Research and Clinical Oncology.

[6]  J. Panse,et al.  High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) , 2016, Leukemia.

[7]  K. Hoang-Xuan,et al.  Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS) , 2016 .

[8]  D. Brat,et al.  Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Y. Kanemura,et al.  Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. , 2016, Molecular and clinical oncology.

[10]  Rose Anne Kenny,et al.  Measurement Error, Reliability, and Minimum Detectable Change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among Community Living Middle-Aged and Older Adults. , 2016, Journal of Alzheimer's disease : JAD.

[11]  M. Pfreundschuh,et al.  High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. , 2016, The Lancet. Haematology.

[12]  Volker W Stieber,et al.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.

[13]  K. Hoang-Xuan,et al.  Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. , 2015, The Lancet. Haematology.

[14]  D. Correa,et al.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. , 2015, Blood.

[15]  I. Date,et al.  Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma , 2014, Clinical Neurology and Neurosurgery.

[16]  M. Taphoorn,et al.  The association between cognitive functioning and health-related quality of life in low-grade glioma patients. , 2014, Neuro-oncology practice.

[17]  M. Taphoorn,et al.  Tumour and surgery effects on cognitive functioning in high-grade glioma patients , 2014, Acta Neurochirurgica.

[18]  A. Brandes,et al.  MATILDE chemotherapy regimen for primary CNS lymphoma , 2014, Neurology.

[19]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[20]  Dale F Kraemer,et al.  Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Correa,et al.  Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Maron,et al.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma , 2013, Neurology.

[23]  A. Vincent,et al.  Cognitive functioning early after surgery of gliomas in eloquent areas. , 2012, Journal of neurosurgery.

[24]  D. Correa,et al.  Cognitive functions in primary CNS lymphoma after single or combined modality regimens. , 2012, Neuro-oncology.

[25]  M. Taphoorn,et al.  Compromised health-related quality of life in patients with low-grade glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Scheithauer,et al.  CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. , 2011, International journal of radiation oncology, biology, physics.

[27]  J. Villano,et al.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma , 2011, British Journal of Cancer.

[28]  M. Reni,et al.  Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. , 2011, International journal of radiation oncology, biology, physics.

[29]  E. Thiel,et al.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.

[30]  R. Fimmers,et al.  Long‐term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma , 2010, Annals of neurology.

[31]  F. Cavalli,et al.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial , 2009, The Lancet.

[32]  J. Reijneveld,et al.  Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings , 2009, Journal of Neuro-Oncology.

[33]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[34]  D. Correa,et al.  Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy , 2009, Journal of Neuro-Oncology.

[35]  F. Feuerhake,et al.  High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system , 2008, Haematologica.

[36]  D. Correa,et al.  Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Correa,et al.  Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Hideaki Takahashi,et al.  Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen , 2007, Leukemia & lymphoma.

[39]  B. O'neill,et al.  Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. , 2004, International journal of radiation oncology, biology, physics.

[40]  J. Armitage,et al.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  K. Fliessbach,et al.  Neuropsychological outcome after chemotherapy for primary CNS lymphoma , 2005, Neurology.

[42]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[43]  E. Neuwelt,et al.  Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. , 2005, AJNR. American journal of neuroradiology.

[44]  D. Nelson,et al.  Secondary Analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma , 2005, Journal of Neuro-Oncology.

[45]  J. Menten,et al.  Cognitive status and quality of life after treatment for primary CNS lymphoma , 2004, Neurology.

[46]  D. Correa,et al.  Cognitive functions in survivors of primary central nervous system lymphoma , 2004, Neurology.

[47]  C. Pollack,et al.  Intravenous Methotrexate as Initial Treatment for Primary Central Nervous System Lymphoma: Response to Therapy and Quality of Life of Patients , 1999, Journal of Neuro-Oncology.

[48]  D. Osoba,et al.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma , 1997, Journal of Neuro-Oncology.

[49]  N. Mackworth,et al.  Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores , 1992, Journal of Neuro-Oncology.

[50]  R. Fimmers,et al.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Zelenetz,et al.  Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. Meyers,et al.  The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  K. Hoang-Xuan,et al.  Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  K. Fliessbach,et al.  Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. , 2003, Archives of neurology.

[55]  T. Batchelor,et al.  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  L. Deangelis,et al.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  R. Fimmers,et al.  Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study , 2001, Journal of neurology, neurosurgery, and psychiatry.

[58]  D. Kraemer,et al.  Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. , 2000, Neurosurgery.

[59]  J. O'fallon,et al.  The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group. , 1999, Neuro-oncology.

[60]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Braziel,et al.  Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. , 1996, The cancer journal from Scientific American.

[62]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[63]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[64]  R. Braziel,et al.  Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Dobson,et al.  Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. , 1981, Journal of chronic diseases.

[66]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.